A Phase II Study of the Therapeutic Effects Of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies

This is a Phase II trial to evaluate the efficacy and safety of human leukocyte antigen (HLA) partially-matched third-party allogeneic Epstein-Barr virus cytotoxic T lymphocytes (EBV-CTLs) for the treatment of EBV-induced lymphomas and EBV-associated malignancies.

Start Date01 Dec 2011

Sponsor / Collaborator

Atara Biotherapeutics, Inc.

[+1]

100 Clinical Results associated with EBV-CTL(Memorial Sloan-Kettering Cancer Center)

100 Translational Medicine associated with EBV-CTL(Memorial Sloan-Kettering Cancer Center)

100 Patents (Medical) associated with EBV-CTL(Memorial Sloan-Kettering Cancer Center)

Literatures (Medical) associated with EBV-CTL(Memorial Sloan-Kettering Cancer Center)

Scientific ReportsQ3 · CROSS-FIELD

Preoperative estimate of natural ureteral length based on computed tomography and/or plain radiography

Q3 · CROSS-FIELD

ArticleOA

Author: Chen, Chien-Wen ; Lin, Wun-Rong ; Tseng, Jen-Shu ; Sun, Fang-Ju ; Chiang, Pai-Kai ; Chiu, Allen W ; Hsu, Jen-Ting ; Chen, Marcelo

AbstractTo predict natural ureter lengths based on clinical images. We reviewed our image database of patients who underwent multiphasic computed tomography urography from January 2019 to April 2020. Natural ureteral length (ULCTU) was measured using a three-dimensional curved multiplanar reformation technique. Patient parameters including age, height, and height of the lumbar spine, the index of ureteral length using kidney/ureter/bladder (KUB) radiographs (C-P and C-PS) and computed tomography (ULCT) were collected. ULCTU correlated most strongly with ULCT. R square and adjusted R square values from multivariate regression were 0.686 and 0.678 (left side) and 0.516 and 0.503 (right side), respectively. ULCTU could be estimated by the regression model in three different scenarios as follows:

ULCT + C-P

ULCTUL = 0.405

$$\times$$

× ULCTL

$$+$$

+ 0.626

$$\times$$

× C-PL – 0.508 cm

ULCTUR = 0.558

$$\times$$

× ULCTR

$$+$$

+ 0.218

$$\times$$

× C-PR + 6.533 cm

ULCT

ULCTUL = 0.876

$$\times$$

× ULCTL

$$+$$

+ 6.337 cm

ULCTUR = 0.710

$$\times$$

× ULCTR

$$+$$

+ 9.625 cm

C-P

ULCTUL = 0.678

$$\times$$

× C-PL

$$+$$

+ 4.836 cm

ULCTUR = 0.495

$$\times$$

× C-PR

$$+$$

+ 10.353 cm

We provide equations to predict ULCTU based on CT, KUB or CT plus KUB for different clinical scenarios. The formula based on CT plus KUB provided the most accurate estimation, while the others had lower validation values but could still meet clinical needs.

100 Deals associated with EBV-CTL(Memorial Sloan-Kettering Cancer Center)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
EBV viremia	Phase 2	US	Atara Biotherapeutics, Inc.	01 Dec 2011
Epstein-Barr virus associated lymphoproliferative disorder	Phase 2	US	Atara Biotherapeutics, Inc.	01 Dec 2011
Epstein-Barr Virus-Related Lymphoma	Phase 2	US	Atara Biotherapeutics, Inc.	01 Dec 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01498484 (CTgov)	Phase 2	Epstein-Barr Virus-Related Lymphoma \| EBV viremia \| Epstein-Barr virus associated lymphoproliferative disorder	87	EBV-specific T cells (EBV-CTLs) (HCT EBV+ PTLD R/R Rituximab)	txbyjxohxu(ryhricxnii) = zjbwfkptoc hfuzpmizkt (lebmalpjwa, zyshnnczmf - ulmnallcmq) View more	-	21 Oct 2022
				EBV-specific T cells (EBV-CTLs) (SOT EBV+ PTLD R/R Rituximab)	txbyjxohxu(ryhricxnii) = czrdzyiizu hfuzpmizkt (lebmalpjwa, kzdfkuwcih - vegqytxlap) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis